---
title: "Olema Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/265145388.md"
published_at: "2025-11-10T12:12:51.000Z"
---

# Olema Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.49, missing the estimate of USD -0.4704.

EBIT: As of FY2025 Q3, the actual value is USD -49.53 M.

### Operating Expenses

-   **Research and Development Expenses**: For the three months ended September 30, 2025, research and development expenses were $39.951 million, an increase from $33.226 million for the same period in 2024, primarily due to higher spending on clinical development activities and personnel-related costs, partially offset by a decrease in stock-based compensation expense.
-   **General and Administrative Expenses**: For the three months ended September 30, 2025, general and administrative expenses were $5.926 million, up from $4.395 million for the same period in 2024, primarily due to higher corporate-related costs and an increase in stock-based compensation expense.

### Other Income

-   **Interest Income**: For the three months ended September 30, 2025, interest income was $3.648 million, compared to $2.928 million for the same period in 2024, reflecting increased interest income from investments.

### Net Loss

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was $42.217 million, compared to $34.555 million for the same period in 2024, primarily due to increased operating expenses.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $108.389 million, compared to - $78.067 million for the same period in 2024, primarily due to increased research and development expenses.
-   **Net Cash Provided by Investing Activities**: For the nine months ended September 30, 2025, net cash provided by investing activities was $6.424 million, compared to $20.898 million for the same period in 2024, primarily due to maturities of marketable securities.
-   **Net Cash Used in Financing Activities**: For the nine months ended September 30, 2025, net cash used in financing activities was - $2.255 million, compared to net cash provided by financing activities of $24.518 million for the same period in 2024, reflecting issuance costs related to the 2024 Private Placement.

### Future Outlook and Strategy

-   **Core Business Focus**: Olema Pharmaceuticals, Inc. plans to continue advancing its lead product candidate, palazestrant, through late-stage clinical development both as a monotherapy and in combination with other targeted agents. The company anticipates top-line results for its pivotal Phase 3 clinical trial, OPERA-01, in the second half of 2026, with a potential FDA approval and commercial launch in late 2027.
-   **Non-Core Business**: The company is also developing OP-3136, a KAT6 inhibitor, with initial clinical results expected in mid-2026. Olema plans to expand its operations and increase its headcount to support ongoing research and development activities.

### Related Stocks

- [OLMA.US - Olema Pharmaceuticals](https://longbridge.com/en/quote/OLMA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Citi, Stifel bullish on Olema (OLMA) despite COO departure | Citi and Stifel analysts remain optimistic about Olema Pharmaceuticals Inc. (NASDAQ:OLMA) despite the recent departure o | [Link](https://longbridge.com/en/news/277249236.md) |
| Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit | Olema Pharmaceuticals CEO Sean Bohen discussed the company's focus on advancing endocrine therapies for ER-positive, HER | [Link](https://longbridge.com/en/news/276712705.md) |
| (INTU) Intuit Expects Fiscal 2026 Adjusted EPS Range $22.98-$23.18 | (INTU) Intuit Expects Fiscal 2026 Adjusted EPS Range $22.98-$23.18 | [Link](https://longbridge.com/en/news/277095431.md) |
| Key facts: Tata Steel Q3 profit jumps to ₹2,730 crore; acquires T Steel shares | Tata Steel's Q3 net profit surged to ₹2,730 crore, up from ₹295 crore last year, while revenue rose over 6% to ₹57,002 c | [Link](https://longbridge.com/en/news/277143847.md) |
| Loch Duart PLC - Q3 report for financial year ending 31 March 2026 | Please find attached the Q3 Interim Report for Loch Duart PLC.For further information please contact: Mark Warrington, C | [Link](https://longbridge.com/en/news/277222090.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.